Time-averaged proteinuria during follow-up and renal prognosis in patients with biopsy-proven benign nephrosclerosis.
Benign nephrosclerosis
Biopsy-proven
Chronic kidney diseases
Proteinuria
Time-averaged proteinuria
Journal
Clinical and experimental nephrology
ISSN: 1437-7799
Titre abrégé: Clin Exp Nephrol
Pays: Japan
ID NLM: 9709923
Informations de publication
Date de publication:
Aug 2020
Aug 2020
Historique:
received:
21
07
2019
accepted:
25
03
2020
pubmed:
11
4
2020
medline:
7
7
2021
entrez:
11
4
2020
Statut:
ppublish
Résumé
Heavy proteinuria at diagnostic renal biopsy has been reported as an independent risk factor for deteriorating renal function in benign nephrosclerosis (BNS). However, studies investigating the relationship between the amount of proteinuria during follow-up and long-term renal prognosis in BNS are limited. This study aimed to assess the relationship between time-averaged proteinuria (TAP) and renal prognosis in BNS. The study participants included 98 patients with biopsy-proven BNS (average age 52 ± 13 years, estimated glomerular filtration rate (eGFR) 53 ± 25 ml/min/1.73 m The average observation period was 56 ± 43 months. In the unadjusted model, higher levels of TAP and urinary protein at baseline, glomerulosclerosis, and tubulointerstitial damage were associated with renal prognosis. The adjusted model demonstrated a significant association between TAP and renal outcomes (hazard ratio 5.45, 95% confidence interval 3.02-10.7), which was independent of higher baseline proteinuria, glomerulosclerosis, and tubulointerstitial damage. TAP is an independent risk factor for renal prognosis in patients with BNS, indicating the significance of urinary protein excretion during follow-up for the progression of BNS. Clinicians should understand the importance of follow-up evaluation for proteinuria in patients with BNS.
Sections du résumé
BACKGROUND
BACKGROUND
Heavy proteinuria at diagnostic renal biopsy has been reported as an independent risk factor for deteriorating renal function in benign nephrosclerosis (BNS). However, studies investigating the relationship between the amount of proteinuria during follow-up and long-term renal prognosis in BNS are limited. This study aimed to assess the relationship between time-averaged proteinuria (TAP) and renal prognosis in BNS.
METHODS
METHODS
The study participants included 98 patients with biopsy-proven BNS (average age 52 ± 13 years, estimated glomerular filtration rate (eGFR) 53 ± 25 ml/min/1.73 m
RESULTS
RESULTS
The average observation period was 56 ± 43 months. In the unadjusted model, higher levels of TAP and urinary protein at baseline, glomerulosclerosis, and tubulointerstitial damage were associated with renal prognosis. The adjusted model demonstrated a significant association between TAP and renal outcomes (hazard ratio 5.45, 95% confidence interval 3.02-10.7), which was independent of higher baseline proteinuria, glomerulosclerosis, and tubulointerstitial damage.
CONCLUSIONS
CONCLUSIONS
TAP is an independent risk factor for renal prognosis in patients with BNS, indicating the significance of urinary protein excretion during follow-up for the progression of BNS. Clinicians should understand the importance of follow-up evaluation for proteinuria in patients with BNS.
Identifiants
pubmed: 32274596
doi: 10.1007/s10157-020-01885-w
pii: 10.1007/s10157-020-01885-w
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
688-695Références
Ruilope LM, van Veldhuisen DJ, Ritz E, Luscher TF. Renal function: the Cinderella of cardiovascular risk profile. J Am Coll Cardiol. 2001;38:1782–7.
doi: 10.1016/S0735-1097(01)01627-8
Shoji T, Abe T, Matsuo H, Egusa G, Yamasaki Y, Kashihara N, et al. Chronic kidney disease, dyslipidemia, and atherosclerosis. J Atheroscler Thromb. 2012;19:299–315.
doi: 10.5551/jat.10454
Iseki K, Ikemiya Y, Iseki C, Takishita S. Proteinuria and the risk of developing end-stage renal disease. Kidney Int. 2003;63:1468–74.
doi: 10.1046/j.1523-1755.2003.00868.x
Liyanage T, Ninomiya T, Jha V, Neal B, Patrice H, Okpechi I, et al. Worldwide access to treatment for end-stage kidney disease: a systematic review. Lancet. 2015;385:1975–82.
doi: 10.1016/S0140-6736(14)61601-9
Ritz E. Minor renal dysfunction: an emerging independent cardiovascular risk factor. Heart. 2003;89:963–4.
doi: 10.1136/heart.89.9.963
Shiraishi N, Kitamura K, Kohda Y, Iseki K, Tomita K. Prevalence and risk factor analysis of nephrosclerosis and ischemic nephropathy in the Japanese general population. Clin Exp Nephrol. 2014;18:461–8.
doi: 10.1007/s10157-013-0833-5
Sumida K, Hoshino J, Ueno T, Mise K, Hayami N, Suwabe T, et al. Effect of proteinuria and glomerular filtration rate on renal outcome in patients with biopsy-proven benign nephrosclerosis. PLoS ONE. 2016;11:e0147690.
doi: 10.1371/journal.pone.0147690
Barbour SJ, Cattran DC, Espino-Hernandez G, Hladunewich MA, Reich HN. Identifying the ideal metric of proteinuria as a predictor of renal outcome in idiopathic glomerulonephritis. Kidney Int. 2015;88:1392–401.
doi: 10.1038/ki.2015.241
Reich HN, Troyanov S, Scholey JW, Cattran DC. The toronto glomerulonephritis registry. Remission of proteinuria improves prognosis in IgA nephropathy. J Am Soc Nephrol. 2007;18:3177–83.
doi: 10.1681/ASN.2007050526
Nishi S, Ubara Y, Utsunomiya Y, Okada K, Obata Y, Kai H, et al. Evidence-based clinical practice guidelines for nephrotic syndrome 2014. Clin Exp Nephrol. 2016;20:342–70.
doi: 10.1007/s10157-015-1216-x
Anonymous. Manual for pathological diagnosis of diabetic nephropathy and hypertensive nephrosclerosis. Nihon Jinzo Gakkai Shi. 2015;57:649–725. (in Japanese)
Vikse BE, Aasarød K, Bostad L, Iversen BM. Clinical prognostic factors in biopsy-proven benign nephrosclerosis. Nephrol Dial Transpl. 2003;18:517–23.
doi: 10.1093/ndt/18.3.517
Kanda E, Usui T, Kashihara N, Iseki C, Iseki K, Nangaku M. Importance of glomerular filtration rate change as surrogate endpoint for the future incidence of end-stage renal disease in general Japanese population: community-based cohort study. Clin Exp Nephrol. 2018;22:318–27.
doi: 10.1007/s10157-017-1463-0
Altman DG, Bland JM. Diagnostic tests 3: receiver operating characteristic plots. BMJ. 1994;309:188.
doi: 10.1136/bmj.309.6948.188
Obuchowski NA, Lieber ML, Wians FH. ROC curves in clinical chemistry: uses, misuses, and possible solutions. Clin Chem. 2004;50:1118–25.
doi: 10.1373/clinchem.2004.031823
Kanda Y. Investigation of the freely available easy-to-use software 'EZR' for medical statistics. Bone Marrow Transpl. 2013;48:452–8.
doi: 10.1038/bmt.2012.244
Matsuzaki K, Suzuki Y, Nakata J, Sakamoto N, Horikoshi S, Kawamura T, et al. Nationwide survey on current treatments for IgA nephropathy in Japan. Clin Exp Nephrol. 2013;17:827–33.
doi: 10.1007/s10157-013-0779-7
Kee YK, Yoon CY, Kim SJ, Moon SJ, Kim CH, Park JT, et al. Determination of the optimal target level of proteinuria in the management of patients with glomerular diseases by using different definitions of proteinuria. Medicine. 2017;96:e8154.
doi: 10.1097/MD.0000000000008154
Momoki K, Kataoka H, Moriyama T, Mochizuki T, Nitta K. Hyperuricemia as a predictive marker for progression of nephrosclerosis: clinical assessment of prognostic factors in biopsy-proven arterial/arteriolar nephrosclerosis. J Atheroscler Thromb. 2017;24:630–42.
doi: 10.5551/jat.37523
Haruhara K, Tsuboi N, Kanzaki G, Koike K, Suyama M, Shimizu A, et al. Glomerular density in biopsy-proven hypertensive nephrosclerosis. Am J Hypertens. 2015;28:1164–71.
doi: 10.1093/ajh/hpu267
Chronic Kidney Disease Prognosis Consortium, Matsushita K, van der Velde M, Astor BC, Woodward M, Levey AS, et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet. 2010;375:2073–81.
doi: 10.1016/S0140-6736(10)60674-5
Bouchi R, Babazono T, Yoshida N, Nyumara I, Toya K, Hayashi T, et al. Association of albuminuria and reduced estimated glomerular filtration rate with incident stroke and coronary artery disease in patients with type 2 diabetes. Hypertens Res. 2010;33:1298–304.
doi: 10.1038/hr.2010.170
Remuzzi G, Bertani T. Pathophysiology of progressive nephropathies. N Engl J Med. 1998;339:1448–566.
doi: 10.1056/NEJM199811123392007
Eddy AA, Giachelli CM. Renal expression of genes that promote interstitial inflammation and fibrosis in rats with protein-overload proteinuria. Kidney Int. 1995;47:1546–57.
doi: 10.1038/ki.1995.218
Abbate M, Zoja C, Remuzzi G. How does proteinuria cause progressive renal damage? J Am Soc Nephrol. 2006;17:2974–84.
doi: 10.1681/ASN.2006040377
Mills KT, Chen J, Yang W, Appel LJ, Kusek JW, Alper A, et al. Sodium excretion and the risk of cardiovascular disease in patients with chronic kidney disease. JAMA. 2016;315:2200–10.
doi: 10.1001/jama.2016.4447
Slagman MC, Waanders F, Hemmelder MH, Woittiez A-J, Janssen WMT, Lambers Heerspink HJ, et al. Moderate dietary sodium restriction added to angiotensin-converting enzyme inhibition compared with dual blockade in lowering proteinuria and blood pressure: randomized controlled trial. BMJ. 2011;343:d4366.
doi: 10.1136/bmj.d4366
Yamanouchi M, Hoshino J, Ubara Y, Takaichi K, Kinowaki K, Fujii T, et al. Clinicopathological predictors for progression of chronic kidney disease in nephrosclerosis: a biopsy-based cohort study. Nephrol Dial Transplant. 2018. https://doi.org/10.1093/ndt/gfy121 .
doi: 10.1093/ndt/gfy121